Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that although more-expensive atypical antipsychotics such as Eli Lilly's Zyprexa, Otsuka Pharmaceutical/Bristol-Myers Squibb's Abilify, Janssen's Risperdal, AstraZeneca's Seroquel, and Pfizer's Geodon will drive the schizophrenia drug market during the period 2003-2013, they will face generic competition by the end of this time frame. According to a new Pharmacor study entitled Schizophrenia, generic erosion will exact a heavy toll on the market because these antipsychotics lose patent protection in 2007 or later.

"Generics will have the greatest impact on the U.S. market, which is the largest and most receptive market for generics," said Michelle Grady, analyst at Decision Resources. "This market will experience a 3.0% annual decline over the period 2008-2013. The launch of depot formulations of atypical antipsychotics and a few other less promising emerging agents will be the only protection against a more precipitous decline."

About Schizophrenia

Virtually all patients require drug therapy to cope with the symptoms of schizophrenia, but as many as 30% of schizophrenia patients are refractory to available drugs. Furthermore, although most physicians agree that current drug therapy adequately addresses the positive symptoms of schizophrenia, these same drugs do not adequately treat the negative symptoms and cognitive dysfunction associated with schizophrenia.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

Roche Group and Merck KGaA to Emerge as Players in the Solid Tumor Drug Market

View Now